Sensei Biotherapeutics (SNSE) 8-K furnishes Q3 2025 results

Sensei Biotherapeutics (SNSE) filed an 8-K announcing it furnished a press release with financial results for the quarter ended September 30, 2025.

Rhea-AI Filing Summary

Sensei Biotherapeutics (SNSE) filed an 8-K announcing it furnished a press release with financial results for the quarter ended September 30, 2025. The disclosure appears under Item 2.02, with the company stating the information "shall not be deemed filed" for purposes of Section 18 of the Exchange Act.

The press release is included as Exhibit 99.1. Sensei’s common stock trades on Nasdaq under the symbol SNSE.

8-K Event Classification

Item 2.02 — Results of Operations and Financial Condition

1 item

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Sensei Biotherapeutics (SNSE) announce in this 8-K?

The company furnished a press release with financial results for the quarter ended September 30, 2025.

Which item of the 8-K covers the SNSE financial press release?

It is disclosed under Item 2.02 (Results of Operations and Financial Condition).

Is the information considered filed under the Exchange Act?

No. The company states the Item 2.02 information "shall not be deemed filed" for purposes of Section 18.

What exhibit contains the press release for SNSE?

The press release is attached as Exhibit 99.1.

On which exchange does SNSE trade and what is its ticker?

Sensei Biotherapeutics’ common stock trades on the Nasdaq under ticker SNSE.

When was the 8-K dated?

The report is dated November 14, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/14/2025 - 07:35 AM EST Learn about SEC filing dates

false 0001829802 0001829802 2025-11-14 2025-11-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 14, 2025

Sensei Biotherapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware		001-39980		83-1863385
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)
1405 Research Blvd, Suite 125 Rockville, MD				20850
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s telephone number, including area code: (240) 243-8000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

Title of each class		Trading symbol		Name of each exchange on which registered
Common Stock		SNSE		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 14, 2025, Sensei Biotherapeutics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1.

The information in this Item 2.02 and the exhibit attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether filed before or after the date hereof and regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Exhibit Description
99.1		Press Release of Sensei Biotherapeutics, Inc., dated November 14, 2025
104		The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						Sensei Biotherapeutics, Inc.
Date: November 14, 2025						/s/ Christopher W. Gerry
						Christopher W. Gerry
						General Counsel and Secretary

3